NEW YORK--(BUSINESS WIRE)--Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B (HBV) and hepatitis D (HDV) infection, today announced that Dr. Andrew Vaillant, Chief Scientific Officer, presented updated clinical data from the REP 301 clinical trial to the Global Virus Hepatitis Summit (15th International Symposium on Viral Hepatitis and Liver Disease) in Berlin Germany. This important conference focusing on the treatment of viral hepatitis occurs every three years.
Help employers find you! Check out all the jobs and post your resume.
